KIMMTRAK
Drug
Immunocore Limited
Total Payments
$4.4M
Transactions
2,185
Doctors
910
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $923,761 | 1,143 | 669 |
| 2023 | $1.6M | 804 | 264 |
| 2022 | $1.8M | 238 | 67 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.7M | 678 | 84.4% |
| Consulting Fee | $485,807 | 161 | 11.1% |
| Honoraria | $91,690 | 67 | 2.1% |
| Food and Beverage | $42,297 | 1,162 | 1.0% |
| Travel and Lodging | $28,195 | 110 | 0.6% |
| Long term medical supply or device loan | $21,548 | 1 | 0.5% |
| Space rental or facility fees (teaching hospital only) | $17,050 | 6 | 0.4% |
Payments by Type
Research
$3.7M
678 transactions
General
$686,587
1,507 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase I/II, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 using the Intra-patient Escalation Dosing Regimen in Patients with Advanced Uveal Melanoma | Immunocore Limited | $1.2M | 1 |
| A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared with Investigators Choice in HLA-A0201 Positive Patients with Previously Untreated Advanced Uveal Melanoma | Immunocore Limited | $944,811 | 0 |
| A Phase Ib/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 in Combination with Durvalumab (MEDI4736) or Tremelimumab or the Combination of Durvalumab and Tremelimumab Compared to IMCgp100 Alone in Patients with Advanced Melanoma | Immunocore Limited | $703,935 | 1 |
| Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) | Immunocore Limited | $570,949 | 0 |
| A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared with Investigators Choice in HLA-A*0201 Positive Patients with Previously Untreated Advanced Uveal Melanoma | Immunocore Limited | $125,845 | 0 |
| Phase II Open-label, Multi-center Study of Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma (mUM) with Integrated Circulating Tumor DNA (ctDNA) Biomaker (TARGET-tebe) | Immunocore Limited | $117,491 | 0 |
Top Doctors Receiving Payments for KIMMTRAK — Page 3
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Medical Oncology | Nashville, TN | $2,800 | 1 |
| , PA | Physician Assistant | Houston, TX | $2,738 | 10 |
| , M.D | Hematology & Oncology | Cleveland, OH | $2,420 | 4 |
| , NP-C | Nurse Practitioner | Houston, TX | $2,408 | 8 |
| , MD | Gastroenterology | Boston, MA | $2,400 | 1 |
| , MD | Internal Medicine | Grand Blanc, MI | $2,300 | 1 |
| , D.O | Internal Medicine | Troy, MI | $2,300 | 1 |
| , M.D | Hematology & Oncology | Iowa City, IA | $2,275 | 4 |
| , D.O | Hematology & Oncology | Jupiter, FL | $2,023 | 2 |
| , MD | Internal Medicine | Madison, WI | $2,000 | 1 |
| , MD | Hematology & Oncology | Aiken, SC | $2,000 | 1 |
| , MD | Internal Medicine | Saint Louis, MO | $1,600 | 1 |
| , MD | Internal Medicine | Wichita, KS | $1,600 | 1 |
| , MD | Hematology & Oncology | Elgin, IL | $1,600 | 1 |
| , MD | Ophthalmology | Memphis, TN | $1,200 | 1 |
| Randy Sweis | Hematology & Oncology | Chicago, IL | $838.74 | 1 |
| , M.D | Ophthalmology | Charlottesville, VA | $705.54 | 4 |
| , M.D | Medical Oncology | Tampa, FL | $612.00 | 1 |
| , M.D | Internal Medicine | Nashville, TN | $446.76 | 6 |
| , M.D., PHD | Medical Oncology | Houston, TX | $287.35 | 1 |
| , PA | Medical | Pittsburgh, PA | $266.93 | 5 |
| James Isaacs | Medical Oncology | Durham, NC | $250.58 | 2 |
| , M.D | Medical Oncology | Cleveland, OH | $250.58 | 2 |
| Dominic Desalle | Physician Assistant | Pittsburgh, PA | $240.87 | 3 |
| , M.D | Hematology | Venice, FL | $224.75 | 1 |
Ad
Manufacturing Companies
- Immunocore Limited $4.4M
Product Information
- Type Drug
- Total Payments $4.4M
- Total Doctors 910
- Transactions 2,185
About KIMMTRAK
KIMMTRAK is a drug associated with $4.4M in payments to 910 healthcare providers, recorded across 2,185 transactions in the CMS Open Payments database. The primary manufacturer is Immunocore Limited.
Payment data is available from 2022 to 2024. In 2024, $923,761 was paid across 1,143 transactions to 669 doctors.
The most common payment nature for KIMMTRAK is "Unspecified" ($3.7M, 84.4% of total).
KIMMTRAK is associated with 6 research studies, including "A Phase I/II, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 using the Intra-patient Escalation Dosing Regimen in Patients with Advanced Uveal Melanoma" ($1.2M).